Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Open-label Dose-ranging Study Evaluating the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics, and Efficacy of CLTX-305 (Encaleret) in Autosomal Dominant Hypocalcemia (ADH) Type 1

NCT04581629 is registered in ClinicalTrials.gov with Calcilytix Therapeutics, Inc., a BridgeBio company as lead sponsor.

NCT NCT04581629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04581629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Open-label Dose-ranging Study Evaluating the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics, and Efficacy of CLTX-305 (Encaleret) in Autosomal Dominant Hypocalcemia (ADH) Type 1
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Phase
Phase 2
Overall status
Completed
Start date
September 20, 2020
Completion date
September 7, 2023
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal dominant hypocalcemia (adh), autosomal dominant hypocalcemia type 1 (adh1)